Literature DB >> 9853931

Adolescents with alpha1-antitrypsin deficiency have high alpha2-macroglobulin and low neutrophil lipocalin and elastase levels in plasma.

T Sveger1, K Ohlsson, E Piitulainen.   

Abstract

Eighteen-year-old adolescents with alpha1-antitrypsin (alpha1AT) deficiency have mostly normal lung function tests. We hypothesized that compensatory increases in other protease inhibitors and/or a decreased leukocyte activity might favorably affect the protease/protease-inhibitor balance in alpha1AT-deficient adolescents. At the age of 18 y 46 PiZZ (severe deficiency), 22 PiSZ (moderate deficiency), and 41 control subjects were studied. The plasma protease inhibitors alpha2-macroglobulin (alpha2M), alpha1-antichymotrypsin (Achy), and secretory leukocyte protease inhibitor (SLPI) were studied, and the protease elastase complexed with alpha1AT (HEAT) and neutrophil gelatinase-associated lipocalin (NGAL) as indicators of neutrophil leukocyte activity. Significantly higher concentrations of alpha2M were found in PiZ (p < 0.0001) and PiSZ (p < 0.0001) individuals compared with control subjects. The PiZZ and SZ adolescents had low levels of NGAL (p < 0.0001). Low levels of HEAT were found in PiZZ subjects (p < 0.0005). Higher concentrations of Achy were found in PiZZ (p < 0.04) and PiSZ (p < 0.05) individuals. Increased concentrations of alpha2M and Achy combined with decreased levels of HEAT and NGAL, indicating decreased leukocyte activity may, to some extent, compensate for the protease/protease inhibitor imbalance in the alpha1AT-deficiency state.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853931     DOI: 10.1203/00006450-199812000-00019

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe alpha1-antitrypsin deficiency.

Authors:  Camilla Hollander; Ulla Westin; Anders Wallmark; Eeva Piitulainen; Tomas Sveger; Sabina M Janciauskiene
Journal:  BMC Pulm Med       Date:  2007-01-29       Impact factor: 3.317

2.  FBG1 Is the Final Arbitrator of A1AT-Z Degradation.

Authors:  John H Wen; Hsiang Wen; Katherine N Gibson-Corley; Kevin A Glenn
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

3.  Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.

Authors:  Behrouz Mostafavi; Sandra Diaz; Hanan A Tanash; Eeva Piitulainen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 4.  Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management.

Authors:  Jan Stolk; Niels Seersholm; Noor Kalsheker
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

5.  Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease.

Authors:  Nan He; Xiaoming Liu; Amber R Vegter; T Idil A Evans; Jaimie S Gray; Junfeng Guo; Shashanna R Moll; Lydia J Guo; Meihui Luo; Ningxia Ma; Xingshen Sun; Bo Liang; Ziying Yan; Zehua Feng; Lisi Qi; Arnav S Joshi; Weam Shahin; Yaling Yi; Katherine N Gibson-Corley; Eric A Hoffman; Kai Wang; Christian Mueller; John F Engelhardt; Bradley H Rosen
Journal:  JCI Insight       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.